D in the LTQOrbitrap had been searched against a smaller database including
D within the LTQOrbitrap were searched against a tiny database like ClpC and also a few other chlamydial proteins. Two putatively substantial matches with sequences containing the canonic Bbinding motif R2 from ClpC have been obtained. Manual inspection in the corresponding MSMS spectra showed an excellent match with all the theoretical fragmentation of only 1 of these sequences, SRLDPVIGR, spanning ClpC residues 203211 (Fig. 2A). A search against the human proteome database did not show a match of this MSMS spectrum with any human peptide. SRLDPVIGR did not match any human sequence upon BLAST analysis, confirming the bacterial origin of this peptide. We next determined no matter if this peptide was just overlooked in our preceding MALDI-TOF comparison or hidden by a co-eluting human HLA-B27 ligand. For this purpose, the RT on the synthetic peptide inside the similar chromatographic condiVOLUME 288 Number 36 SEPTEMBER 6,25814 JOURNAL OF BIOLOGICAL CHEMISTRY70 EG ) FP-5 (1 pc Cl pC12 :05 B 27 Cl (EGFP)-Chlamydial HLA-B27 LigandsAx5 x100 95 90 85 80472.b541.y5 ay7 y6 yy3 y2 yS R L D P V I G Rb2 b3 b4 b5 b6 b7 bRelative Abundance70 65 60 55 50 45 40 35 30 25 20 15 10 five 0 200 300 400 500 600 700 800 900b4-NH455.BMH-H2Ob4-H2O y8-H2O497.454.a62 320.b7H2O400.yb2-NH227.b3-NHy1-NH157.232.y340.b7 769.48 781.40 b7-NH3 668.47 764.47 y6 656.44 a7 753.59 a6 b5 569.38 640.54 by95y6 y5 y4 y3 yy3 345.175.b8H2O856.Relative Abundanceb2 y2-NH3 244.21 b52 215.27 285.29 y345.13 357.b838.b85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 ten five 0S R L D P V I G Rb2 b3 b4 b5 b6 bmzx5 x100 95 90 85541.32 472.by5 ay7 y6 yy3 y2 yb42 236.y2 y3 173.21 232.S R L D P V I G Rb2 b3 b4 b5 b6 b7 by52 a52 271.31 b2 244.18 b52 285.b72 391.39 b4 472.27 a72 377.52 b3 y4 357.32 a4 444.400b5 569.29 y5 a5 541.38 b6 y6 668.39 656.600 700 800 900 1000Relative LPAR1 drug Abundance75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 200b4-NH455.PV-28 169.PV 197.200b4-H2O y8-H2O454.mzb7H2O400.320.86 345.a6yb2-NH227.b3-NH340.MH-NH3497.y6 y5 y4 y3 yy1-NH175.Relative Abundancey3 232.20 y3-NH3 345.32 158.15 328.33 y2-NH3 b2 b3 215.15 244.22 2 357.35 b5 yy668.41 656.y6 aby7 b7 769.48 781.90 85 80 75 70 65 60 55 50 45 40S R L D P V I G Rb2 b3 b4 b5 b6 bb7-NH764.a838.CCR3 Biological Activity b8H2Ob285.569.400 500 600 700b640.753.856.mzx5 x100 95 90 85541.34 472.by5 ay7 y6 yy3 y2 y30 25 20 15236.72 173.PV-28 y2 y32 232.b4271.b2 244.y52 a5391.40 472.32 377.42 357.b3 a72 bb7S R L D P V I G Rb2 b3 b4 b5 b6 b7 b569.y5 ab169.285.PV 197.b5Relative Abundance75 70 65 60 55 50 45 40 35 30 25 20 15 ten 5 0 200b4-NH455.5 0444.300 400y4 a668.45 656.600 700 800 900 1000b541.yb4-H2O y8-H2Omz454.b7H2O2 b2-NH400.227.b3-NHy1-NH158.y -NH 345.38 y2-NH3 b2 3328.343 215.18 244.22 b3 y1 357.35 175.19 b5232.y340.MH-NH3498.yb7 668.48 769.53 781.55 y6 656.45 b7-NH3 b8 838.58 764.47 a6 640.by285.569.b753.700ab8H2O856.mzFIGURE 2. Identification in the chlamydial B27:05 ligand SRLDPVIGR from ClpC(112) transfectant cells. A, MSMS spectra of the [M 2H]2 ion peaks at mz 506.80 detected in the LTQ-Orbitrap in the unfractionated HLA-B27 peptidome (top rated) or in the LTQ-Velos from fraction 142 in the HPLC-fractionated HLA-B27 peptidome (middle) along with the synthetic SRLDPVIGR peptide, corresponding to residues 20311 from the ClpC protein (bottom). B, MSMS spectrum on the [M 3H]3 ion peak at mz 338.20 detected in a pool of HPLC fractions in the RT 3 min on the synthetic peptide, using an LTQ-Velos mass spectrometer (leading) and of the synthetic peptide corresponding to residues 20311 in the ClpC protein (bottom).